- Home
- BEP vs EXEL Comparison
BEP vs EXEL Comparison
Compare BEP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEP | EXEL |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | Canada | United States |
| Employees | 5870 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.4B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | BEP | EXEL |
|---|---|---|
| Price | $33.41 | $44.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 21 |
| Target Price | $35.70 | ★ $46.50 |
| AVG Volume (30 Days) | 636.1K | ★ 2.1M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $17.09 | $13.61 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | ★ N/A | $16.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.17 | $33.76 |
| 52 Week High | $35.97 | $48.74 |
Technical Indicators
Market Signals| Indicator | BEP | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 53.56 |
| Support Level | $32.27 | $40.98 |
| Resistance Level | $35.97 | $46.46 |
| Average True Range (ATR) | 0.92 | 1.45 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 28.11 | 36.29 |
Price Performance
Historical ComparisonAbout BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.